source
- Odyssey Therapeutics raises $279 million in IPO, adds $25 million private saleOdyssey Therapeutics, a biotech focused on autoimmune diseases, completed an initial public offering that generated $279 million by selling 15.5 million shares at $18 each. The company also secured…
- Pierre Fabre aligns with FDA on resubmission of Ebvallo cell therapyPierre Fabre Laboratories announced that it has reached an agreement with the U.S. Food and Drug Administration on a new path for its cell therapy Ebvallo, which had been rejected twice. The FDA w…